- Select a blog category
By Mark Steedman, PhD, Research Manager, Centre for Health Solutions
“Alexa… Volume up!”
Like many children his age, my four-year old nephew loves the Frozen soundtrack, and he recently figured out how to turn up the volume from anywhere in the room without having to be close to the speaker. He uses the voice assistant that’s always on and always listening.
By Elizabeth Hampson, Director, Monitor Deloitte
Yesterday was Time to Talk Day (7th February) – a day to encourage everyone in the UK to talk about mental health.1 This week is also Child and Adolescent Mental Health Week (4-10 February) and, in view of my interests in mental health and wellbeing, this week’s blog provides an overview of recent developments and insights about mental health and resilience in children and young people.
By Greg Reh, vice chairman, US and Global Life Sciences leader, Deloitte LLP
This week’s blog, by Deloitte’s global Life Sciences leader Greg Reh, first appeared on the US Center for Health Solutions blog site.1 The blog presents his take on the findings from our 2018 Measuring the return from pharmaceutical innovation 2018 report, and what strategies pharma can use to improve their return on investment from R&D.
By Karen Taylor, Director, Centre for Health Solutions
Last week we provided an update on the three health care predictions from our November 2017 report - The future awakens: Life Sciences and health care predictions 2022. As promised, this week’s blog reviews developments during 2018 on the three predictions that are more life sciences focused and what we might expect to see in 2019.
By Karen Taylor, Director, Centre for Health Solutions
As 2019 gets firmly underway I thought it would be interesting to revisit the six predictions in our November 2017 report, The future awakens: Life Sciences and health care predictions 2022, examine relevant developments in 2018 and consider what might happen in 2019. Over the past 14 months or so, the scale of change is escalating at such a pace that some of the predictions are closer to being realised that initially anticipated, while others may well be overtaken by events. While the predictions are relevant to all stakeholders across health care and life sciences, I have split them into two groups, the three more health care focussed ones are the subject of this week’s blog and next week will be the turn of our three more life sciences focused, ones.
By Elizabeth Hampson, Director, Monitor Deloitte and Amen Sanghera, Centre for Health Solutions
This week, we launched our report Patient access to innovative medicine in Europe: A collaborative and value-based approach, which examines the challenges European payers and the pharma industry are facing in funding and bringing the latest innovations to market. Moreover, the report also looks at how key industry stakeholders can work in innovative ways to ensure patients have access to the latest medical innovations.
By Matthew Thaxter, Centre for Health Solutions
This week, we published our ninth annual report on Measuring the return from pharmaceutical innovation. Our report tracks the projected return on investment that the 12 leading biopharma companies (by 2009 R&D spend) might expect to achieve from their late-stage pipelines. For the fourth consecutive year, we also track the performance of an extension cohort of four more specialised biopharma companies. This week’s blog summarises the key findings from the 2018 report.
By Li Xiaofeng, Manager, Monitor Deloitte, London and David Xie, Director, Monitor Deloitte, Shanghai
China has rapidly become one of the larges biopharmaceuticals (biopharma) and medical products markets in the world and is projected to reach $145-175 billion in sales by 2022 (representing a compound annual growth rate of more than 5.5 percent from 2017).1 Profound changes, particularly in relation to shortening the time taken to obtain regulatory approval and widening market access, are making China a more attractive market for biopharma companies to launch innovative medical products. Indeed, since 2017, China has approved record numbers of innovative foreign drugs.2,3 These approvals follow a series of policy moves to provide public funding to enable China’s 1.4 billion population to access new, lifesaving drugs, especially cancer therapies. However many drug makers have had to slash prices so that government will cover the costs of some of the advanced treatments.4
As our parents age, health care stakeholders should determine how to connect with them…and with us (their caregivers)
By Claudia Douglass, Managing Director, Deloitte Consulting LLP
This week’s blog, by Claudia Douglas a Managing Director within the Deloitte US firm, first appeared on the US Center for Health Solutions blog site.1 The blog looks at how health care stakeholders can better connect with patients and carers who are unengaged with technological solutions and the benefits they can provide.
My Take: Highlights from the 2018 FT Conference panel discussion on the potential for a successful life sciences economy in the UK
By John Haughey, Deloitte Industry Leader, Life Sciences & Health Care
Earlier this month I had the pleasure of chairing a panel of life science experts at the Global Financial Times Pharmaceutical and Biotechnology conference.1 The conference brought together some of our industry’s leading minds to discuss the commercial conundrums of disease prevention, the transformational impact of advanced gene and cell therapies and the hope and hype of patient-centricity. The discussion topic for my panel was - ‘Big Bang? Industrial Strategy - Creating a Successful Life Sciences Economy’, and was focused on the UK’s Industrial Strategy and in particular the UK’s sector deal for life sciences.2 In this week’s blog I wanted to share some of my key takeaways from our animated and insightful discussion.